SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid tumors.
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.
AbbVie has discontinued an ongoing phase 3 trial evaluating its antibody drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M) for the treatment of newly diagnosed glioblastoma (GBM), an aggressive type of brain cancer, owing to futility.
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Melior Pharmaceuticals I, a US-based mid-stage biopharma company, said that its insulin sensitizer, tolimidone (MLR-1023) has succeeded in a phase 2b trial in Type 2 diabetes mellitus (T2DM).
Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced positive results of an ex-U.S. proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED).
Novartis today announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).
Vifor Pharma announced that its hypertension and chronic kidney disease (CKD) drug Veltassa (patiromer) has met its primary endpoint in phase II Amber study.
Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) plus radiation has failed to meet its primary endpoint of overall survival (OS) in phase 3 brain cancer trial.
Merck, known as MSD outside of the US and Canada, announced results from a Phase 2 trial (NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.